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Background: The aim was to survey current practice in glucocorticoid replacement therapy and self-perceived
health outcomes in patients with adrenal insufficiency.
Methods: Participants were recruited via patient organizations to respond anonymously to a web-based survey
developed by clinical experts. Unique entries were set up for each patient organization enabling geographical
localization of the entries.
Results: 1245 participants responded (primary adrenal insufficiency: 84%; secondary adrenal insufficiency: 11%;
unsure: 5%). Therapies included hydrocortisone (75%), prednisone/prednisolone (11%), cortisone acetate (6%) and
dexamethasone (4%). Dosing regimens were once daily (10%), twice daily (42%), thrice daily (32%) or other (17%).
Compromised subjective health necessitating changes to physical activity or social-, work- or family life was
reported by 64% of the participants. 40% of the participants reported absence from work/school in the last
3 months. Irrespective of diagnosis, 76% were concerned about long-term side-effects of therapy, mainly
osteoporosis (78%), obesity (64%) and cardiovascular morbidity (46%). 38% of the participants had been hospitalized
in the last year.
Conclusions: Glucocorticoid replacement therapy among the respondents consisted primarily of hydrocortisone
administered twice or thrice daily. A majority reported impact of their disease or treatment on subjective health
requiring alterations in e.g. physical activity or family life. Three quarters reported concerns about long-term
side-effects of the treatment. These data demonstrate - from the patients' perspective - a need for improvement
in the management of adrenal insufficiency.Background
Recent data indicate that replacement therapy with glu-
cocorticoids in adrenal insufficiency (AI) is associated
with poor long-term outcome. In the two largest
registry-based studies on mortality in patients with
Addison's disease, the relative risk of death was more
than 2-fold compared to the background population
despite treatment [1,2]. Patients with hypopituitarism
and secondary AI also have increased relative risk of
death [3]. Based on the increase in cardiovascular risk* Correspondence: maria.forss@duocort.com
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reproduction in any medium, provided the orfactors [4,5] and reduced bone mineral density (mainly
in female AI patients) [6-10], overly high glucocorticoid
exposure is likely to occur at least during parts of the
day/night. This is supported by data showing an inverse
relationship between dose exposure and bone mineral
density [7]. Due to the short half-life of hydrocortisone,
each oral dose is followed by a rapid increase and often
an overly high peak in serum cortisol concentration
followed by a rapid decline. Multiple doses of
immediate-release hydrocortisone tablets are needed in
order to cover the active part of the day but result in a
peak after each dose and a trough between doses. It has
been estimated that AI patients are on average over-
substituted by 6-7 mg hydrocortisone/day based on and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Besides symptoms indicating over-exposure to glucocor-
ticoids, e.g. a tendency to gain weight, symptoms indi-
cating underexposure, e.g. salt craving, were also
commonly reported in a previous survey [12].
The subjective health-related quality of life (QoL) of
AI patients is impaired on a group level [13-16] with
health scores inferior to those of the background popu-
lation. General health and vitality have been found to be
consistently impaired [13], with fatigue being the most
characteristic subjective health feature of AI [12,13].
Working ability is reduced to various degrees in different
countries [11-14]. Attempts to re-establish the normal
cortisol exposure-time profile have in an open study
demonstrated improvement in well-being [17], and
improved QoL was observed in another study when
changing from a twice daily (BID) to a thrice daily (TID)
regimen [18]. These data suggest that the peaks and
troughs between doses may to some extent explain the
poor self-perceived well-being reported by patients.
The aim of this patient survey was to investigate
current practice in glucocorticoid replacement therapy
(therapy and dosage regimen) in patients with primary
or secondary AI in different countries and the partici-
pants’ self-perceived health status and outcomes by type
of disease and therapy.
Methods
This was an open cross-sectional survey. Participants
were recruited via patient organizations (e-mail contact
lists and newsletters) to respond anonymously to the
web-based survey. The following patient organizations
actively approached their members to participate in the
survey and had links to the survey on their home page:
National Adrenal Diseases Foundation (NADF) in the
US, Australian Addison’s Disease Foundation, Addison’s
Disease Self Help Group (ADSHG) in the UK and Cush-
ing’s Support and Research Foundation (CSRF) in the
US. Some additional patient organizations also had in-
formation about and/or links to the survey on their re-
spective websites: CARES foundation in the US,
Association Surrénales in France, two Swedish associa-
tions (The Swedish Addison Association and Hypofysis),
two Danish associations (Addisonforeningen in Den-
mark and Danish Morbus Addison Site), the Dutch
Addison & Cushing Society (NVACP) and Associazioni
Italiana Pazienti Addison in Italy. A link was also set up
on the sponsor’s website for other patients wanting to
complete the survey.
The questionnaire covered a range of questions (39
questions in total), including patient demographics
(country, type of disease, etc.), medication and satisfac-
tion with the current medication. It also covered impact
of the disease on self-perceived subjective health, theprevalence and impact of fatigue, views on long-term
side effects related to treatment, hospitalizations and ab-
senteeism from work or school. The questionnaire con-
sisted of a mix of single select, multiple select and open
questions. A pilot survey was conducted with four mem-
bers from different patient organizations to ensure the
validity of the questions in the questionnaire. Revisions
were then made to the questionnaire before the survey
was conducted. In order to ensure the privacy of the
participants’ contact details, it was agreed that each pa-
tient organization should send out alerts via e-mail and
newsletters to inform its members about the survey and
its objectives. Although no research ethics committee
approval is needed for the conduct of this kind of patient
survey [19], a research application had to be completed
for the UK patient organization ADSHG, in order to be
able to recruit volunteers from their membership regis-
try. No remuneration was given to the participants. No
data on age and gender were collected in order to fur-
ther protect the individual identity of the participants.
Unique links for each patient organization were set up
in the web survey tool Easyresearch (by QuestBack,
Oslo, Norway), the technical platform used for adminis-
tration and analysis of the survey. The unique entries
enabled geographical localization of the entries. The
intention was to have the survey open for approximately
6 weeks, but the survey opening time was extended as a
result of the high degree of interest from individual
patients and additional patient organizations. The survey
was open from September 12th to December 19th 2008.
The data were analyzed descriptively (frequency ana-
lysis) by disease type (primary or secondary AI), treat-
ment and dosing regimen. The country-specific analyses
included only countries with more than 20 participants.
The denominator for the calculation of frequency varied
between the questions since not all participants
answered all questions. The asking of some of the ques-
tions, such as on subjective general health, was
dependent on previous answers (e.g. degree of impact on
QoL was only asked if the participant had answered that
the disease affected their QoL). No statistical tests were
performed.
Results
A total of 1281 persons visited the webpage of the sur-
vey whereof 1245 responded to at least the first question
(“In which country do you live?”). The respondents were
from (by number of participants): US (801), Australia
(90), France (81), UK (80), Canada (37), Sweden (35),
Denmark (19), the Netherlands (8), Germany (7), Bel-
gium (6), New Zealand (5), Mexico (4), Ecuador (3), Ire-
land (3), Spain (3), Chile (2), Dominican Republic (2),
India (2), Norway (2), Philippines (2), Poland (2), South
Africa (2), Switzerland (2), Argentina (1), Dubai (1),







n (%) n (%) n (%) n (%)
(N = 772) (N= 116) (N = 60) (N= 1042)
Once daily 47 (6%) 35 (30%) 4 (7%) 104 (10%)
Twice daily 304 (39%) 61 (53%) 44 (73%) 437 (42%)
Thrice daily 301 (39%) 6 (5%) 8 (13%) 328 (32%)
Other 120 (16%) 14 (12%) 4 (7%) 173 (17%)
Note: The number of patients recording dosing regimen was not the same as
the number of patients reporting therapy (Table 1).
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Martinique (1), Portugal (1), Serbia (1) and Uruguay (1).
When asked “What type of cortisol deficiency are you
suffering from?”, 939 participants (84%) defined their AI
as primary (Addison’s disease, congenital adrenal hyper-
plasia, adrenal disease causing dysfunction of adrenal
glands or removed glands) and 125 (11%) as secondary
(pituitary or hypothalamic disease) while 51 (5%) were
unsure.
Glucocorticoid treatment regimen
Overall, hydrocortisone was used by 75% of the partici-
pants, prednisone/prednisolone by 11%, cortisone acet-
ate by 6% and dexamethasone by 4% of the participants,
Table 1. A high proportion of participants (40%) in Aus-
tralia reported using cortisone acetate. Among the coun-
tries with at least 20 respondents, the use of prednisone/
prednisolone was most common in Canada (27%), the
US (14%) and Australia (11%) and dexamethasone was
most commonly used in Australia (5%) and the US (4%).
The distribution of therapies was similar between
patients with primary and secondary AI. The majority of
the patients were on BID (42%), or TID (32%), while
10% were on an OD regimen, Table 1. Of the patients on
a BID regimen, 58% took their medication in the morn-
ing and afternoon and 42% in the morning and evening.
Patients with secondary AI took their BID dosing in the
morning and afternoon (39%) rather than in the morn-
ing and evening (9%). 53% of the patients on prednis-
one/prednisolone were on BID and 5% on TID. For
treatment regimen by therapy, please see Table 2.
One quarter (23%) of the participants were dissatisfied
or very dissatisfied with their current treatment, 18%Table 1 Therapy and dosing regimen, by type of adrenal
insufficiency, reported in an international patient survey
Primary AI Secondary AI All
n (%) n (%) n (%)
Therapy Hydrocortisone 697 (75%) 98 (80%) 833 (75%)
Prednisone,
prednisolone
100 (11%) 12 (10%) 124 (11%)
Cortisone acetate 57 (6%) 4 (3%) 63 (6%)
Dexamethasone 35 (4%) 4 (3%) 39 (4%)
Other 38 (4%) 4 (3%) 50 (5%)
N N= 927 N= 122 N= 1109
Dosing
regimen
Once daily 80 (9%) 14 (12%) 104 (10%)
Twice daily 360 (42%) 58 (48%) 437 (42%)
Thrice daily 291 (34%) 25 (21%) 328 (32%)
Other 135 (16%) 23 (19%) 173 (17%)
N N= 866 N= 120 N= 1042
Note: The number of patients responding to the question about therapy was
not the same as the number of patients reporting dosing regimen (different
questions).were indifferent and 59% were satisfied or very satisfied.
Patients with secondary AI reported less satisfaction
with their current therapy than patients with primary
AI. The ratings of satisfaction were similar among the
different therapies.
Multiple daily dosing was reported as a problem by
38% of the participants whereof 15% were on OD, 35%
on BID, 32% on TID and 17% on another regimen. Of
those who did not find multiple daily dosing to be a
problem 7% were on OD, 45% on BID, 32% on TID and
16% on another regimen. Among respondents answering
that multiple daily dosing was a problem 94% reported
one or more of the following: difficulties to remember/
forgetting doses (particularly the midday and afternoon
doses), difficulties in taking the medication at a specific
time every day and/or difficulties to remember to bring
the medication. Many reported that their days are
planned according to their dose intake and for those
who lead a busy life and are working, this was found to
be challenging as some also reported that they do not
want to be seen by their colleagues when taking their
medication. Several reported that multiple daily dosing
becomes very restrictive to an active life and that mul-
tiple daily dosing is a reminder several times per day that
they have this disease. Many also reported health issues
such as being fatigue and exhausted in the day, evening
and the following day(s) if missing a dose. In addition,
many reported that taking a missed dose too late dis-
rupts their sleep and causes issues with insomnia. Some
reported instability of physical and mental well-being
with mood swings and ups and downs in energy levels.
The patients who reported multiple daily dosing to be a
problem also reported higher frequencies of impacted
QoL, more fatigue and more activities altered due to
their disease (data not shown).
Enduring efficacy over 24 hours was considered
the most important feature of an optimal replacement
medication (29%) followed by few side effects (25%)
and low risk of adrenal crisis (22%). Similar responses
were obtained from patients with primary and second-
ary AI.
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A majority of the patients (648 of 1026 [64%]) reported
impacted quality of life (QoL) due to their illness, 87%
(99 of 114) of patients with secondary AI and 60% (515
of 857) of the patients with primary AI. Approximately
three quarters (73 of 99 [74%]) of the patients with sec-
ondary AI graded the impact on QoL as “quite a lot” or
“very much”, Table 3. The proportion of patients who
reported impaired QoL varied with dosing regimen (OD
>BID>TID). However, the level of impairment did not
differ between the dosing regimens. A lower proportion
of patients treated with hydrocortisone reported
impaired QoL compared with patients receiving corti-
sone acetate or prednisone/prednisolone but the level of
impairment did not differ between the therapies (data
not country-adjusted).
All patients were asked “What activities do you need
to alter due to your AI?”, regardless of whether they had
answered that their QoL was impaired or not. A large
percentage of the participants reported that they had
had to alter their physical activity (56%), social life
(40%), work life (39%) or family life (31%) due to their
illness (the participants were allowed to choose more
than one alternative). A higher proportion of patients
with secondary AI (90%) than with primary AI (68%)
reported that they had had to alter work life, social life,
physical activity or family life, Figure 1.
A majority of the participants reported fatigue in the
morning (57%) and during the day (65%) to be a prob-
lem. Fatigue was more pronounced in patients with sec-
ondary AI than in patients with primary AI, Table 4. Of
those reporting morning fatigue to be a problem, 75%
also reported fatigue during the day to be a problem.
Similarly, of those reporting fatigue during the day to be
a problem, 85% also reported morning fatigue to be a
problem.
In this survey, 61% of the respondents considered
themselves fit to work while 17% did not. Additionally
5% of the respondents both considered themselves unfit
to work and were on sick leave, 10% were retired and
7% were unemployed. Of those considering themselvesTable 3 Impact of adrenal insufficiency on quality of life
(QoL) captured in an international survey
Primary AI Secondary AI All
n (%) n (%) n (%)
Impact on QoL Yes 515 (60%) 99 (87%) 658 (64%)
N N= 857 N= 114 N=1026
Degree of
impacton QoL
A little 73 (14%) 10 (10%) 86 (13%)
Intermediate 170 (33%) 16 (16%) 195 (30%)
Quite a lot or
very much
267 (52%) 73 (74%) 372 (57%)
N N= 510 N= 99 N=653fit to work, 72% considered themselves fit to work full-
time, while 18% could work 75%, 9% could work 50%
and 1% could work <50%. Overall, 40% of the partici-
pants had been absent from work in the last 3 months
and, again, this was more common among patients suf-
fering from secondary AI (50%) than for patients with
primary AI (38%). Almost one third (28%) of those being
away from work or school reported more than 3 weeks’
absence in the 3 months preceding their participation in
the survey, Table 5. A higher percentage of patients trea-
ted with prednisone/prednisolone reported absenteeism
compared with patients on hydrocortisone and they also
reported more lengthy absenteeism (data not shown).
A majority of the participants were worried about
long-term side effects. The participants were most wor-
ried about osteoporosis (79%), followed by obesity (64%),
fatigue (52%) and cardiovascular problems (46%) (more
than one alternative could be chosen), Table 6. A higher
proportion of those treated with prednisone/prednisol-
one were worried about long-term side effects than
those treated with hydrocortisone (data not shown).
Overall, 32% of the participants reported that they
increased their dose due to physical activity at least once
per week (primary AI patients: 30%; secondary AI
patients: 49%) and 66% increased their dose due to ill-
ness at least once per month (primary AI patients: 65%;
secondary AI patients: 76%).
Overall, 38% of the participants responding to the
question about hospitalizations (N= 977) answered that
they had been hospitalized at least once during the last
12 months (37% of patients with primary AI and 43% of
patients with secondary AI). One third of the patients
(32%) had been hospitalized more than once during the
last 12 months. The reported reason for hospitalization
was adrenal crisis, vomiting or an acute infection for
17% of the patients who had been hospitalized.
Discussion
The conduct of this survey was similar to previous
cross-sectional surveys with participants recruited via
patient organizations [5,11,12]. The current survey of
1245 respondents is to our knowledge the largest patient
survey to date in patients with AI. Previous studies have
shown that outcomes in patients with AI are compro-
mised [12-14]. The responses from this survey provide
more information on the impact of the disease and its
treatment on patient-perceived outcomes, and support
previous data showing a large impact of the disease and
its treatment on the daily life of these patients.
Therapy traditions differ to some extent between
countries but hydrocortisone was the most commonly
used therapy in this survey (75%), irrespectively of coun-
try, which is also in line with previous studies from Eur-
ope [4,20]. The distribution of therapies, i.e. type of
Figure 1 Change in activities due to adrenal insufficiency. Responses to the question “What activities do you need to alter due to your
adrenal insufficiency”? in an international patient survey. A total of 1001 subjects responded to this question.
Table 5 Absenteeism from work or school due to adrenal
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mary and secondary AI. Three quarters of the patients
were on a BID or TID regimen. One unexpected obser-
vation in this survey was the high percentage (58%) of
patients on prednisone/prednisolone who were on a BID
or TID regimen.
That multiple daily dosing is a problem from a compli-
ance point of view is well known from other therapies
[21]. The free-text answers to the open questions of this
survey confirmed that multiple daily dosing is not opti-
mal in AI and has an impact on patients’ social life and
work life. More specifically, 4 of 10 patients in this sur-
vey found multiple daily dosing to be a problem. The
impact on leading a normal life was attributed both to
multiple dosing and to fluctuations in mental/physical
energy over the day as multiple daily dosing with hydro-
cortisone/cortisone acetate causes peaks and low trough
values in-between dosing occasions. When asked about
the most important features of an optimal replacement
medication, the patients ranked efficacy over 24 hours first
and few side effects second. More patients on TID were
satisfied with their treatment compared to those on BID
or OD treatment. This might be attributable to the better
cortisol coverage of TID during the active part of the day
[22,23] over the convenience of fewer dosing times.
The results from this survey are in line with a recently
published clinical study [24] which showed that aTable 4 Fatigue in the morning and during the day
reported by patients with adrenal insufficiency in an
international patient survey
Primary AI Secondary AI All
n (%) n (%) n (%)
Fatigue experienced
as a problem in the
morning
Yes 438 (53%) 91 (81%) 571 (57%)
N N= 832 N= 113 N= 998
Fatigue experienced
as a problem during
the day
Yes 508 (61%) 99 (87%) 644 (65%)
N N= 830 N= 114 N= 995majority of the patients preferred the four-daily dosing
regimen to twice daily when comparing equal doses of
hydrocortisone given either twice daily or four times
daily. The reasons reported were less fatigue, more alert-
ness during the day, less headache and a feeling that the
treatment effect was less varying during the day. The
patients had complaints after the study that a four-dose
regimen may be difficult to manage in the long run [24].
Another study has shown that a thrice-daily administra-
tion with weight-adjusted doses provides a better PK
profile within the constraints of immediate-release
hydrocortisone formulations [25]. 85% of the patients
opted to remain on the TID regimen given in that study.
These data suggest that patients experience benefits of
having increased cortisol coverage during the active part
of the day. One caveat of the above studies is that the
total exposure of cortisol is higher when the same daily
dose of hydrocortisone is administered divided into
three or four daily doses than at BID administration.
This is due to the fact that increasing the dose of hydro-
cortisone at one dose occasion does not result in a pro-
portional increase in total exposure of cortisol due to
the non-linear bioavailability of orally administered
hydrocortisone [26]. Thus, there might be a short-terminsufficiency in the last 3 months reported in an
international patient survey
Primary AI Secondary AI All
n (%) n (%) n (%)
Any abseenteism Yes 299 (38%) 54 (50%) 379 (40%)
N N= 796 N= 108 N= 951
No. of days
of abseenteism
1-5 174 (59%) 17 (33%) 198 (53%)
6-10 37 (13%) 6 (12%) 46 (12%)
11-15 16 (5%) 5 (10%) 23 (6%)
>16 70 (24%) 24 (46%) 107 (29%)
N N= 297 N= 52 N= 374
Table 6 Worries about long-term effects reported by
patients with adrenal insufficiency in an international
patient survey
Primary AI Secondary AI Respondents
n (%) n (%) n (%)
Any worry Yes 612 (75%) 93 (82%) 740 (76%)




Osteoporosis 477 (79%) 76 (82%) 578 (79%)
Obesity 374 (62%) 72 (77%) 464 (64%)
Fatigue 301 (50%) 63 (68%) 381 (52%)
Cardiovascular 258 (43%) 58 (62%) 334 (46%)
Infectious
disease
230 (38%) 52 (56%) 300 (41%)
Other 117 (20%) 15 (16%) 138 (19%)
N N= 601 N= 93 N=728
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whereas the long-term risk may increase.
It is difficult to mimic physiological cortisol profiles
with immediate release hydrocortisone replacement ther-
apies [22,25]. Therefore, attempts to better mimic the
normal cortisol profiles have been made by developing
new treatment regimens using the concept of chronother-
apy, i.e. considering circadian rhythms in determining the
timing and amount of the medication to optimize the
desired effects and minimize the undesired ones [17,27].
A once-daily treatment with dual action, combining im-
mediate release and extended release hydrocortisone has
shown benefit over immediate release hydrocortisone
with the same daily dosing administered thrice daily in
patients with adrenal insufficiency [28].
Two thirds of the participants reported impacted QoL
from their illness. In line with this being a patient survey
(capturing the patient’s general perception of their sub-
jective health at only one time point) and not a clinical
trial, the questionnaire used in this survey did not in-
clude validated QoL questions from specific QoL ques-
tionnaires. Instead, the included questions were focused
on the patients’ general perception of how and to what
degree their disease and/or treatment affected their
QoL. This survey showed that patients with secondary
AI perceived their QoL as more impaired than patients
with primary AI, which is in agreement with a previous
study using validated QoL questionnaires showing that
patients with AI have compromised QoL and that the
impairment of QoL is worse in patients with secondary
AI [14]. The current survey did not collect data on co-
morbidities. Patients with secondary adrenal insuffi-
ciency may have other hormone deficiencies which could
impact on QoL. However, data from previous studies are
inconsistent and while some impact was observed in a
Norwegian study of patients with Addison’s disease [13],
another study [14] showed that the impairment inhealth-related subjective health status in AI patients is
largely independent of concomitant diseases.
More than half of the AI patients needed to alter their
physical activity and many needed to change their social
life, work life or family life due to their illness. The level
of impact on social life is in line with data from another
international survey, conducted in 2003, in which one-
third reported that their condition impacted on their
ability to participate in social activities [29]. A Dutch pa-
tient survey reports similar impact on lifestyle [5].
Detailed questions on fatigue were included in the
current survey as fatigue is the most commonly reported
subjective health-related problem in AI [5,11-13,29,30].
This survey showed that 57% of the participants experi-
enced fatigue in the morning as a problem and 65%
reported fatigue during the day to be a problem. This re-
sponse is in some contrast to the general perception that
morning fatigue is a much larger clinical problem than
fatigue during the day in patients with AI who have low
or undetectable serum morning cortisol levels when
using hydrocortisone BID or TID. Fatigue was more
common in secondary AI than in primary AI and often
necessitated changes in daily activities or changes in
dose or the timing of dosing.
The current survey demonstrated a high absenteeism
from work or school. More specifically, 4 of 10 patients
reported absenteeism from work or school due to AI in
the last 3 months and one third of those reported more
than 3 weeks’ absence. Furthermore, 17% of the partici-
pants did not consider themselves to be fit to work.
Among those who considered themselves fit to work,
28% worked part-time instead of full-time. These data
are similar to those of a survey conducted across the
UK, Canada, Australia and New Zealand (n = 850) [29],
in which over 10% of the respondents reported that they
were unable to work compared with 1% in the matched
control group. Moreover, in the study by Hahner et al.
[14], 18% of the AI patients (primary and secondary) did
not work vs. 4% in the general population. In a Norwe-
gian study, working disability amounted to 26% among
patients with primary AI vs. 10% in the general popula-
tion [13].
Patients with AI are educated to increase their gluco-
corticoid dose in stressful situations and in association
with other illnesses. This survey showed that 60-75% of
the patients increased their replacement dose due to ill-
ness every month. The high rate of hospitalizations in
this survey (38% of the patients had been hospitalized at
least once in the last year) is in line with the Dutch sur-
vey in which 3 of 10 patients had been hospitalized [5].
The reported reason for hospitalization was adrenal cri-
sis, vomiting or an acute infection in 17% of the patients.
As a comparison, the incidence rate of adrenal crises
was 6.3 per 100 patient years in a study by Hahner et al.
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differences in methods of collecting data and that the
definition of adrenal crisis is not the same, e.g. only
cases of hospitalization necessitating i.v. glucocorticoid
administration were counted as adrenal crises in the
study by Hahner.
Because of the relatively small disease population, age
and gender were not included in the questionnaire in
order to protect personal integrity and anonymity. Inter-
net use and behaviours linked to it are hypothetical con-
founding factors in the interpretation of the survey
results. Patients who seek information about their dis-
ease usually tend to be more active than other patients,
which can also affect the results. Despite the fact that
congenital adrenal hyperplasia (CAH) constitutes one
form of primary AI, it would have been interesting to
analyse data on this patient group separately as recent
data published by Arlt et al. (2010) showed significantly
impaired health status and adverse metabolic and skel-
etal health in adult CAH patients [32], however, data
were not separately collected for patients with CAH in
this survey.Conclusions
This international survey showed that the glucocorticoid
replacement regimens in AI differ to some degree be-
tween countries. Three quarters of the AI patients par-
ticipating in the survey received hydrocortisone
administered two or three times daily. A large majority
of the participants reported that their disease and the
current treatment have an impact on QoL leading to
alterations in physical activity, social life, work life and
family life. Furthermore, 76% of the participants
reported concerns of long-term side-effects of their
treatment. These data demonstrate - from the AI
patients' perspective – an obvious need for improvement
in the management of AI including the regimen of
glucocorticoid replacement therapy.
Competing interests
This survey was funded by DuoCort Pharma. MF works for DuoCort Pharma
AB. GB, SS and GJ have equity interests in DuoCort AB.
Acknowledgements
We thank the participants in the survey and the patient organizations
supporting their members to participate and share their experience. We also
thank Karin Gewert, Writewise, who provided medical writing services on
behalf of DuoCort Pharma.
Author details
1DuoCort Pharma, Medicinaregatan 8A, 413 46, Gothenburg, Sweden.
2Department of Clinical Pharmacology, Sahlgrenska Academy, University of
Gothenburg, Gothenburg, Sweden. 3Department of Endocrinology,
Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Authors’ contributions
All authors contributed to the design of the survey and writing/review of the
manuscript. All authors read and approved the final manuscript.Received: 14 November 2011 Accepted: 13 June 2012
Published: 13 June 2012
References
1. Bergthorsdottir R, Leonsson-Zachrisson M, Odén A, Johannsson G:
Premature mortality in patients with Addison's disease: a population-
based study. J Clin Endocrinol Metab 2006, 91:4849–4853.
2. Bensing S, Brandt L, Tabaro F, Sjöberg O, Nilsson B, Ekbom A, Blomqvist P,
Kämpe O: Increased death risk and altered cancer incidence pattern in
patients with isolated or combined autoimmune primary adrenocortical
insufficiency. Clin Endocrinol (Oxf ) 2008, 69:697–704.
3. Mills JL, Schonberger LB, Wysowski DK, Brown P, Durako SJ, Cox C, Kong F,
Fradkin JE: Long-term mortality in the United States cohort of pituitary-
derived growth hormone recipients. J Pediat 2004, 144:430–436.
4. Filipsson H, Monson JP, Koltowska-Häggström M, Mattsson A, Johannsson
G: The impact of glucocorticoid replacement regimens on metabolic
outcome and comorbidity in hypopituitary patients. Clin Endocrinol Metab
2006, 91:3954–3961.
5. Holleman J: Illness, healthcare, and the quality of life. In A survey among
patients with Addison’s disease, Cushing’s syndrome or congenital adrenal
Hyperplasia (CAH). the Netherlands: Dutch Addison and Cushing Society:
NVACP; 2006 (English version: November 2007). ISBN 90-78441-02-X.
6. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA: Effect of glucocorticoid
replacement therapy on bone mineral density in patients with Addison
disease. Ann Intern Med 1994, 120:207–210.
7. Løvås K, Gjesdal CG, Christensen M, Wolff AB, Almås B, Svartberg J, Fougner
K, Syversen U, Bollerslev J, Falch JA, Hunt PJ, Chatterjee VKK, Husebye ES:
Glucocorticoid replacement therapy and pharmacogenetics in Addison's
disease: effects on bone. Eur J Endocrinol 2009, 160:993–1002.
8. Devogelaer JP, Crabbé J, Nagant de Deuxchaisnes C: Bone mineral density
in Addison's disease: evidence for an effect of adrenal androgens on
bone mass. Br Med J (Clin Res Ed) 1987, 294:798–800.
9. Florkowski CM, Holmes SJ, Elliot JR, Donald RA, Espiner EA: Bone mineral
density is reduced in female but not male subjects with Addison's
disease. N Z Med J 1994, 107:52–53.
10. Ragnarsson O, Nyström HF, Johannsson G: Glucocorticoid replacement
therapy is independently associated with reduced bone mineral density
in women with hypopituitarism. Clin Endocrinol (Oxf ) 2012, 76:246–252.
11. Wass J, White K, Elliott A, Baker S, Arlt W, Chatterjee K, Croxson M, Gurnell E,
Hunt P, Howlett T: Medication management and quality of life in patients
with primary adrenal insufficiency. In International Addison’s survey 2003.
2005. Poster presentation in Harrogate 2005. http://www.addisons.org.uk/
comms/meetings/harrogateposter2005.pdf.
12. Margulies PL, Mullen J, National Adrenal Diseases Foundation: North
American survey of individuals with Addison's disease. 1997. http://www.nadf.
us/news/survey1997_text.pdf.
13. Løvås K, Loge JH, Husebye ES: Subjective health status in Norwegian
patients with Addison's disease. Clin Endocrinol (Oxf ) 2002, 56:581–588.
14. Hahner S, Loeffler M, Fassnacht M, Weismann D, Koschker AC, Quinkler M,
Decker O, Arlt W, Allolio B: Impaired subjective health status in 256
patients with adrenal insufficiency on standard therapy based on cross-
sectional analysis. J Clin Endocrinol Metab 2007, 92:3912–3922.
15. Gurnell EM, Hunt PJ, Curran SE, Conway CL, Pullenayegum EM, Huppert FA,
Compston JE, Herbert J, Chatterjee VKK: Long-term DHEA replacement in
primary adrenal insufficiency: a randomized, controlled trial. J Clin
Endocrinol Metab 2008, 93:400–409.
16. Erichsen MM, Løvås K, Skinningsrud B, Wolff AB, Undlien DE, Svartberg J,
Fougner KJ, Berg TJ, Bollerslev J, Mella B, Carlson JA, Erlich H, Husebye ES:
Clinical, immunological, and genetic features of autoimmune primary
adrenal insufficiency: observations from a Norwegian registry. J Clin
Endocrinol Metab 2009, 94:4882–4890.
17. Løvås K, Husebye ES: Continuous subcutaneous hydrocortisone infusion
in Addison's disease. Eur J Endocrinol 2007, 157:109–112.
18. Groves RW, Toms GC, Houghton BJ, Monson JP: Corticosteroid
replacement therapy: twice or thrice daily? J R Soc Med 1988, 81:514–516.
19. British Healthcare Business Intelligence Association (BHBIA): Legal and ethical
guidelines for healthcare market research. October 2011th edition. http://
www.bhbia.org.uk/guidelines/legalandethicalguidelines.aspx.
20. Reynolds RM, Stewart PM, Seckl JR, Padfield PL: Assessing the HPA axis in
patients with pituitary disease: a UK survey. Clin Endocrinol (Oxf ) 2006,
64:82–85.
Forss et al. BMC Endocrine Disorders 2012, 12:8 Page 8 of 8
http://www.biomedcentral.com/1472-6823/12/821. World Health Organization: Adherence to long-term therapies: evidence for
action. Geneva, Switzerland: 2003. http://www.who.int/chp/knowledge/
publications/adherence_full_report.pdf.
22. Simon N, Castinetti F, Ouliac F, Lesavre N, Brue T, Oliver C: Pharmacokinetic
evidence for suboptimal treatment of adrenal insufficiency with
currently available hydrocortisone tablets. Clin Pharmacokinet 2010,
49:455–463.
23. Blomgren J, Ekman B, Andersson PO, Arnqvist HJ: Non-physiological levels
of circulating cortisol in growth hormone-treated hypopituitary adults
after conventional cortisone substitution. Scand J Clin Lab Invest 2004,
64:132–139.
24. Ekman B, Bachrach-Lindström M, Lindström T, Wahlberg J, Blomgren J,
Arnqvist HJ: A randomized double blind crossover study comparing two
and four dose hydrocortisone regimen with regard to quality of life,
cortisol and ACTH profiles in patients with primary adrenal insufficiency.
Clin Endocrinol (Oxf ) 2012, 77:18–25.
25. Mah PM, Jenkins RC, Rostami-Hodjegan A, Newell-Price J, Doane A,
Ibbotson V, Tucker GT, Ross RJ: Weight-related dosing, timing and
monitoring hydrocortisone replacement therapy in patients with adrenal
insufficiency. Clin Endocrinol (Oxf ) 2004, 61:367–375.
26. Toothaker RD, Craig WA, Welling PG: Effect of dose size on the
pharmacokinetics of oral hydrocortisone suspension. J Pharm Sci 1982,
71:1182–1185.
27. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ,
Newell-Price J, Darzy K, Merke DP, Arlt W, Ross RJ: Modified-release
hydrocortisone to provide circadian cortisol profiles. J Clin Endocrinol
Metab 2009, 94:1548–1554.
28. Johannsson G, Nilsson AG, Bergthorsdottir R, Burman P, Dahlqvist P, Ekman
B, Engström BE, Olsson T, Ragnarsson O, Ryberg M, Wahlberg J, Biller BM,
Monson JP, Stewart PM, Lennernäs H, Skrtic S: Improved cortisol exposure-
time profile and outcome in patients with adrenal insufficiency: a
prospective randomized trial of a novel hydrocortisone dual-release
formulation. J Clin Endocrinol Metab 2012, 97:473–481.
29. White KG, Wass JAHW, Elliott AE, Baker SJK: Medication management and
quality of life in patients with primary adrenal insufficiency. British
Endocrine Societies Joint Meeting. In Endocrine Abstracts 9 P142. 2005.
http://www.endocrine-abstracts.org/ea/0009/ea0009p142.htm.
30. Løvås K, Curran S, Oksnes M, Husebye ES, Huppert FA, Chatterjee VK:
Development of a disease-specific quality of life questionnaire in
Addison's disease. J Clin Endocrinol Metab 2010, 95:545–551.
31. Hahner S, Loeffler M, Bleicken B, Drechsler C, Milovanovic D, Fassnacht M,
Ventz M, Quinkler M, Allolio B: Epidemiology of adrenal crisis in chronic
adrenal insufficiency: the need for new prevention strategies. Eur J
Endocrinol 2010, 162:597–602.
32. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV,
Conway GS, Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ: United
Kingdom Congenital Adrenal Hyperplasia Adult Study Executive
(CaHASE): Health status of adults with congenital adrenal hyperplasia: a
cohort study of 203 patients. J Clin Endocrinol Metab 2010, 95:5110–5121.
doi:10.1186/1472-6823-12-8
Cite this article as: Forss et al.: Current practice of glucocorticoid
replacement therapy and patient-perceived health outcomes in adrenal
insufficiency - a worldwide patient survey. BMC Endocrine Disorders 2012
12:8.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
